BioSpace News Archive

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com . A replay of the webcast will be archived for 30 days foll

First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAE), high dose cohort safety analysis ongoing Subject screening is ongoing for Phase I expansion cohorts Phase 2 / 3 hAd5 COVID-19 trial in design

CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced publication of detailed interim Phase 1 data, following the reporting of positive topline data on November 2, 2020.

BetterLife Pharma Inc. an emerging biotech company focused on development and commercialization of interferon based treatments, announced a clinical and regulatory update for its AP-003 COVID-19 clinical trials following discussions with the U.S Food and Drug Administration.

After four weekly intravenous doses of DNL310, a 76% mean reduction in CSF GAG levels (heparan sulfate) from baseline was observed, with normal healthy levels being achieved in four of five patients Based on Cohort A safety data review, an independent data monitoring committee recommended continuing the study without modifications, enabling progression to Cohort B,

- 35 % of subjects treated with VP-102 achieved complete clearance of all treatable genital warts vs 2. 4 % for vehicle (p=0.0001) - - VP-102 was well-tolerated with no reported serious adverse events related to VP-102 - - Approximately 500,000 to 1 million cases of EGW are newly diagnosed per year in the United States - - Based on positive outcome, Verrica will request an End - of - Phase 2 meeting with the FDA -

Data From 100-Patient Randomized, Controlled Trial on Nonhealing Diabetic Foot Ulcers Presented at SAWC Fall 2020

Former Biotech CEO and senior Merck executive James (Jay) Galeota joins Board of Directors

Continued to enroll and dose patients in Phase 1/2 clinical trial of BDTX-189, with Phase 1 portion on track to complete by first half of 2021 Strengthened Board of Directors with appointment of Robert A. Ingram as Chairman Bolstered executive team with appointment of Rachel Humphrey, M.D., as Chief Medical Officer Cash, cash equivalents, and investments of $333.1 million as of September 30, 2020, expected to be sufficient to fund operations into 2023

Arch Therapeutics, Inc., developer of novel self-assembling wound care and biosurgical devices, announces that it has raised approximately $1.1M from long-term shareholders.